Medical Devices; Neurological Devices; Classification of the Transcutaneous Electrical Nerve Stimulator To Treat Fibromyalgia Symptoms
Key claim: The FDA is classifying the transcutaneous electrical nerve stimulator for fibromyalgia symptoms into Class II (special controls) to provide reasonable assurance of safety and effectiveness while enhancing patient access.
Abstract
(Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is classifying the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients’ access to beneficial innovative devices, in part by reducing regulatory burdens.
Why this matters
Classifying TENS devices for fibromyalgia into Class II with special controls creates a defined regulatory pathway that lets manufacturers clear these devices via 510(k) rather than premarket approval, which typically speeds market entry and broadens patient access to non-pharmacologic pain treatment options. For patients with fibromyalgia — a chronic pain condition with limited effective therapies — this may translate into more available devices and potentially more insurance-covered options over time.